South Africa leads backlash against big pharma over Covid vaccine access

Pressure mounts for patent waivers to allow poorer countries to develop their own manufacturing capacity to boost availability

The domination of global medicine by major pharmaceutical companies needs to be confronted to provide fairer access to vaccines, a leading South African official has said.

The scramble over Covid vaccines should alert rich countries to the power of profit-driven companies that control production of crucial medicines, said Mustaqeem De Gama, South Africa’s delegate at the World Trade Organization (WTO) on intellectual property rights.

“While Rome is burning, we are fiddling around [waiting],” said De Gama, who called on nations where many of these pharmaceutical firms are based to stop blocking a patent waiver proposed at the WTO.

Backed by dozens of developing countries, the proposal, introduced by South Africa and India, argued that bypassing intellectual property rights would allow more of the world’s population to be quickly vaccinated by boosting production.

“The first effective vaccines were ready four or five months ago. Do you think it would have made a difference if we had the capacity to manufacture? I certainly think so.”

Supplies are low after rich countries bought more vaccines than they needed to, leading to predictions that many low-income countries may not be able to reach mass immunisation until 2024.

Some vaccines are being provided to low- and middle-income countries through donations, largely through the Covax initiative led by Gavi, the Vaccine Alliance – a public-private global health partnership. But many argue the donations are too few and rely on stock unused by rich countries.

De Gama said more structural change was needed to enable countries to make their own vaccines instead of relying on terms set by donors or profit-driven companies.

“The infrastructure right now is providing a minimum and leaving the rest to the private sector,” said De Gama. “I don’t think governments should be outsourcing their responsibility for public health to private companies who are responsible to shareholders only.”

He said the recent sale of AstraZeneca vaccines to South Africa at double the price paid by European countries was evidence of the need for more transparency in how decisions on supplies and pricing are made.

Médecins Sans Frontières (MSF) on Thursday called for urgent delivery of vaccines to lower-income countries in order to avoid further mutations of the coronavirus, such as the 501Y.V2 variant that has spread throughout southern Africa since being identified in December.

Prominent South African businesswoman Yamkela Makupula said many were angered at not being able to access vaccines while hospitals and the economy were suffering, hit by the wave of Covid-19 linked to the new variant.

“Most countries across the world are facing recession while having to deal with the effects of the pandemic. So to only vaccinate a portion of the world and leave the rest to fend for themselves with limited resources is a very flawed strategy,” she said.

“There is no amount of economic recovery strategies that can save South Africa where it is right now. What is imperative is to get our people vaccinated in order to not only rebuild the economy but to save people’s lives.”

Shehnaaz Peer, a GP in Eastern Cape province, said the vaccine “really translates into hope” after seeing a rise in cases, more patients with prolonged Covid symptoms and increasing mental health challenges, especially among young people.

Roz Scourse, a policy adviser for MSF Access, said the EU had been “hypocritical” in its recent outrage over undelivered AstraZeneca vaccines while blocking the proposed patent waiver, alongside other countries that host big pharmaceutical companies, including the UK.

“This is really showing the EU and other rich countries what happens when you hand over all the rights and control of the manufacture and distribution of Covid vaccines in the time of a pandemic to huge multinational corporations,” said Scourse.

Zain Rizvi, who works on access to medicine at US-based advocacy group Public Citizen, said governments should have demanded more open access from pharmaceutical companies because much of the funding for the initial research and development came from public funding.

“Rich countries had tremendous leverage when they were giving funding to these organisations,” he said. “I can’t emphasise enough how outrageous it is that there are vaccine shortages when there is capacity just sitting there. It’s morally bankrupt.”

Contributor

Kaamil Ahmed

The GuardianTramp

Related Content

Article image
Big pharma fuelling human rights crisis over Covid vaccine inequity – Amnesty
Six companies warned not to put profit before lives as report shows less than 1% of almost 6bn doses have gone to low-income countries

Sarah Johnson

22, Sep, 2021 @10:46 AM

Article image
‘Like copying a Louis Vuitton handbag’: big pharma hits out at Africa’s replica Covid vaccine
Knowledge-sharing hub in Cape Town reverse engineered the Moderna vaccine, but future of the initiative to reduce inequity remains unsure

Sarah Johnson in Cape Town

05, Oct, 2022 @6:30 AM

Article image
Homegrown Covid vaccines fill gap as UN Covax scheme misses target
India, Egypt and Brazil among countries developing and making their own vaccines after Covax falls behind

Hazem Badr, Helen Mendes and Papiya Bhattacharya

13, Oct, 2021 @6:00 AM

Article image
Harry and Meghan add voices to fierce critique of west’s Covid vaccine policies
Pair join Gordon Brown and 127 others in attack on ‘self-defeating nationalism, pharmaceutical monopolies and inequality’

Sarah Johnson

11, Mar, 2022 @12:01 AM

Article image
We are seeing a global vaccine apartheid. People’s lives must come before profit | Winnie Byanyima
The poorest countries are missing out on adequate doses of vaccines and the health implications should concern us all

Winnie Byanyima

29, Jan, 2021 @7:45 AM

Article image
‘They thought Covid only kills white people’: myths and fear hinder jabs in DRC
Mutant strain may emerge amid vaccine hesitancy, experts say, as even medics reject jabs in DR Congo

Lisa Murray in Kinshasa

05, Aug, 2021 @6:00 AM

Article image
Oxford Covid vaccine has 10% efficacy against South African variant, study suggests
Small-scale trial of vaccine shows it offers very little protection against mild to moderate infection

Kevin Rawlinson and Ian Sample

08, Feb, 2021 @1:54 PM

Article image
Oxford AstraZeneca vaccine to be sold to developing countries at cost price
Jab that is part of global initiative to distribute doses will remain at low price ‘in perpetuity’

Peter Beaumont

23, Nov, 2020 @4:14 PM

Article image
Omicron seems to carry higher Covid reinfection risk, says South Africa
Scientists warn of higher rate of repeat infections but say vaccines appear to protect against serious illness

Peter Beaumont and Nick Dall in Cape Town

02, Dec, 2021 @6:23 PM

Article image
Pfizer accused of holding Brazil ‘to ransom’ over vaccine contract demands
Leaked supply document reveals clauses to protect US pharma company from legal action in the event of serious side-effects

Mattha Busby and Flávia Milhorance in Rio de Janeiro

10, Sep, 2021 @5:01 AM